Background: The aim of this study was to assess the plasma levels of factor VIII (FVIII), von Willebrand factor (vWF) and their association in patients with cerebral venous sinus thrombosis (CVST). Methods: We prospectively included 25 CVST patients admitted to the university hospital and 53 voluntary subjects as a control group. FVIII and vWF were measured after 6 months when anticoagulant therapy was stopped. Results: The mean FVIII and vWF levels were significantly higher in the CVST group compared to the control group (126.21 ± 54.69 vs. 91.9 ± 48.8 IU/dl; p = 0. 012; 157.05 ± 107.74 vs. 94 ± 84%; p = 0.01, respectively). Using analyses calculating the 95th percentile cut-off values, we found high levels of FVIII in patients compared to controls (29.2 vs. 5%; p = 0.01) and the odds ratio with 95% confidence interval (CI) was 7.82 (1.46, 41.6). After adjustment for vWF levels, sex and age, the risk remained significantly increased and the odds ratio with 95% CI was 10.5 (1.1, 101.4) (p = 0.041). Conclusion: FVIII is one of the most prevalent risk factors of CVST and may be associated with an approximately tenfold increased risk for developing CVST. This effect is independent of vWF levels; however, vWF is not an independent risk factor of CVST.

Keywords:
Cerebral venous and sinus thrombosis, Factor VIII, Von Willebrand factor
1.
Janghorbani M, Zare M, Saadatnia M, Mousavi SA, Mojarrad M, Asgari E: Cerebral vein and dural sinus thrombosis in adults in Isfahan, Iran: frequency and seasonal variation. Acta Neurol Scand 2008;117:117–121.
2.
Saadatnia M, Mousavi SA, Haghighi S, Aminorroaya A: Cerebral vein and sinus thrombosis in Isfahan, Iran: a changing profile. Can J Neurol Sci 2004;31:474–477.
3.
Fatehi F, Basiri K, Saadatnia M, Koleini N: Cerebral venous thrombosis associated with oligodendroglioma and pregnancy. Neurosciences (Riyadh) 2009;14:277–279.
4.
Saadatnia M, Fatehi F, Basiri K, Mousavi SA, Mehr GK: Cerebral venous sinus thrombosis risk factors. Int J Stroke 2009;4:111–123.
5.
Kim MJ, Cho AH, No YJ, Kim HY, Kim JS: Recurrent cerebral venous thrombosis associated with elevated factor VIII. J Clin Neurol 2006;2:286–289.
6.
Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR: Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995;345:152–155.
7.
O’Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M: High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997;77:825–828.
8.
Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, et al: Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002;113:636–642.
9.
Bugnicourt JM, Roussel B, Tramier B, Lamy C, Godefroy O: Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case-control study. J Neurol Neurosurg Psychiatry 2007;78:699–701.
10.
Burns A, Wilson E, Harber M, Brunton C, Sweny P: Cerebral venous sinus thrombosis in minimal change nephrotic syndrome. Nephrol Dial Transplant 1995;10:30–34.
11.
Ehler E, Kopal A, Mrklovský M, Kostál M: Cerebral venous thrombosis after a cesarean delivery. Acta Medica (Hradec Kralove) 2010;53:109–113.
12.
Kanazawa K, Takubo H, Nakamura Y, Ida M: Cerebral venous thrombosis with elevated factor VIII. Intern Med 2010;49:1461–1462.
13.
Kraaijenhagen RA, in’t Anker PS, Koopman MM, Reitsma PH, Prins MH, van den EA, et al: High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000;83:5–9.
14.
Cakmak S, Derex L, Berruyer M, Nighoghossian N, Philippeau F, Adeleine P, et al: Cerebral venous thrombosis: clinical outcome and systematic screening of prothrombotic factors. Neurology 2003;60:1175–1178.
15.
Martinelli I: Von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 2005;42:49–55.
16.
Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, et al: Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999;81:680–683.
17.
Eischer L, Gartner V, Schulman S, Kyrle PA, Eichinger S: Six versus thirty months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. Ann Hematol 2009;88:485–490.
18.
Hoppener MR, Kraaijenhagen RA, Hutten BA, Buller HR, Peters RJ, Levi M: Beta-receptor blockade decreases elevated plasma levels of factor VIII:C in patients with deep vein thrombosis. J Thromb Haemost 2004;2:1316–1320.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.